xamoterol has been researched along with bepridil in 1 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (bepridil) | Trials (bepridil) | Recent Studies (post-2010) (bepridil) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 798 | 70 | 94 |
| Protein | Taxonomy | xamoterol (IC50) | bepridil (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | 1.4 | |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 1 | |
| Lethal factor | Bacillus anthracis | 4.8 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 1 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.5184 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 1 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 1.2 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 3.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
1 other study(ies) available for xamoterol and bepridil
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |